Literature DB >> 3300308

Review of the bioavailability and pharmacokinetics of oral norfloxacin.

G E Stein.   

Abstract

The pharmacokinetic profile of norfloxacin, an oral fluoroquinolone, is more complex than that of many antibacterial agents. Following administration of a 400-mg dose, peak serum concentrations of 1.5 to 2.0 micrograms/ml are achieved within one to two hours. The drug is widely distributed throughout the body, achieves high ratios of tissue to serum concentrations in both renal and prostatic tissue, and undergoes metabolic conversion. Six metabolites of norfloxacin have been identified. Approximately 30 percent of an administered dose is excreted as unchanged drug by glomerular filtration and tubular secretion. Following a single dose of norfloxacin, therapeutic levels of drug in the urine are achieved rapidly and maintained for at least 12 to 24 hours. Norfloxacin has a terminal elimination half-life of approximately three hours, although the presence of a reduced glomerular filtration rate increases the elimination half-life. Dosage modification is, therefore, necessary when the glomerular filtration rate falls below 20 ml/minute.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3300308     DOI: 10.1016/0002-9343(87)90613-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

Review 1.  Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

2.  Square-wave adsorptive anodic stripping voltammetric determination of norfloxacin using a glassy carbon electrode modified with carbon black and CdTe quantum dots in a chitosan film.

Authors:  Anderson Martin Santos; Ademar Wong; Fernando Henrique Cincotto; Fernando Cruz Moraes; Orlando Fatibello-Filho
Journal:  Mikrochim Acta       Date:  2019-02-02       Impact factor: 5.833

3.  Norfloxacin: a new quinolone. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.

Authors: 
Journal:  CMAJ       Date:  1988-08-15       Impact factor: 8.262

4.  A norfloxacin dose finding study for selective decontamination of the digestive tract in pigs.

Authors:  L A Van der Waaij; O Messerschmidt; D Van der Waaij
Journal:  Epidemiol Infect       Date:  1989-02       Impact factor: 2.451

5.  Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers.

Authors:  Max Taubert; Joseph Chiesa; Mark Lückermann; Carsten Fischer; Axel Dalhoff; Uwe Fuhr
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

6.  Norfloxacin interaction with antacids and minerals.

Authors:  N R Campbell; M Kara; B B Hasinoff; W M Haddara; D W McKay
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

Review 7.  Pharmacokinetics of quinolones: newer aspects.

Authors:  J S Wolfson; D C Hooper
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 8.  Absorption interactions with fluoroquinolones. 1995 update.

Authors:  B M Lomaestro; G R Bailie
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

Review 9.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

10.  Effect of Tinidazole on Norfloxacin Disposition.

Authors:  Sally Aly Helmy; Mona Ibrahim El-Assal
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.